InterCure Ltd. (INCR)
USD 1.6
(1.27%)
USD 1.6
(1.27%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 94.53 Million ILS | 318.85% |
| 2022 | 22.57 Million ILS | 125.85% |
| 2021 | -87.3 Million ILS | -179.74% |
| 2020 | -31.2 Million ILS | -203.38% |
| 2019 | -10.28 Million ILS | -209.89% |
| 2018 | 9.36 Million ILS | 1051.0% |
| 2017 | 813.29 Thousand ILS | 297.6% |
| 2016 | -411.58 Thousand ILS | 84.79% |
| 2015 | -2.7 Million ILS | -1977.66% |
| 2014 | 144.07 Thousand ILS | 118.81% |
| 2013 | -766.15 Thousand ILS | 66.6% |
| 2012 | -2.29 Million ILS | -105.86% |
| 2011 | 39.14 Million ILS | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 113.17 Million ILS | 15.68% |
| 2024 Q1 | 113.17 Million ILS | 63.41% |
| 2023 Q3 | 89.89 Million ILS | 49.36% |
| 2023 Q2 | 60.18 Million ILS | -32.19% |
| 2023 FY | 94.53 Million ILS | 318.85% |
| 2023 Q1 | 88.75 Million USD | 293.22% |
| 2023 Q4 | 69.25 Million ILS | -22.96% |
| 2022 Q3 | -14.01 Million ILS | 76.57% |
| 2022 Q4 | 22.57 Million ILS | 261.0% |
| 2022 Q1 | -83.18 Million ILS | 4.72% |
| 2022 Q2 | -59.82 Million ILS | 28.08% |
| 2022 FY | 22.57 Million ILS | 125.85% |
| 2021 Q3 | -129.5 Million ILS | 12.84% |
| 2021 Q4 | -87.3 Million ILS | 32.59% |
| 2021 Q1 | -29.41 Million ILS | 5.74% |
| 2021 FY | -87.3 Million ILS | -179.74% |
| 2021 Q2 | -148.57 Million ILS | -405.04% |
| 2020 FY | -31.2 Million ILS | -203.38% |
| 2020 Q2 | 8.23 Million ILS | 3503.31% |
| 2020 Q3 | -29.15 Million ILS | -453.99% |
| 2020 Q4 | -31.2 Million ILS | -7.05% |
| 2020 Q1 | -242 Thousand ILS | 97.65% |
| 2019 FY | -10.28 Million ILS | -209.89% |
| 2019 Q3 | -3.26 Million ILS | 91.24% |
| 2019 Q4 | -10.28 Million ILS | -215.17% |
| 2019 Q1 | 7.23 Million ILS | -22.74% |
| 2019 Q2 | -37.25 Million ILS | -615.11% |
| 2018 Q2 | 1.76 Million ILS | -49.36% |
| 2018 Q3 | 9.36 Million ILS | 430.9% |
| 2018 Q4 | 9.36 Million ILS | 0.0% |
| 2018 FY | 9.36 Million ILS | 1051.0% |
| 2018 Q1 | 3.48 Million ILS | 328.14% |
| 2017 Q1 | 2.57 Million ILS | 726.55% |
| 2017 Q3 | 854 Thousand ILS | -65.61% |
| 2017 Q4 | 813.29 Thousand ILS | -4.77% |
| 2017 FY | 813.29 Thousand ILS | 297.6% |
| 2017 Q2 | 2.48 Million ILS | -3.7% |
| 2016 Q3 | 1.73 Million ILS | 40.14% |
| 2016 FY | -411.58 Thousand ILS | 84.79% |
| 2016 Q4 | -411.58 Thousand ILS | -123.73% |
| 2016 Q2 | 1.23 Million ILS | 98.42% |
| 2016 Q1 | 623.79 Thousand ILS | 123.06% |
| 2015 Q4 | -2.7 Million ILS | 66.85% |
| 2015 Q3 | -8.16 Million ILS | 1.28% |
| 2015 Q1 | -13.58 Million ILS | -9528.19% |
| 2015 FY | -2.7 Million ILS | -1977.66% |
| 2015 Q2 | -8.26 Million ILS | 39.15% |
| 2014 Q4 | 144.07 Thousand ILS | 144.32% |
| 2014 Q3 | 58.96 Thousand ILS | 329.46% |
| 2014 Q2 | 13.73 Thousand ILS | 101.81% |
| 2014 Q1 | -759.88 Thousand ILS | 0.82% |
| 2014 FY | 144.07 Thousand ILS | 118.81% |
| 2013 Q4 | -766.15 Thousand ILS | -70.42% |
| 2013 FY | -766.15 Thousand ILS | 66.6% |
| 2013 Q1 | -1.16 Million ILS | 49.03% |
| 2013 Q2 | -1.36 Million ILS | -17.01% |
| 2013 Q3 | -449.56 Thousand ILS | 67.14% |
| 2012 FY | -2.29 Million ILS | -105.86% |
| 2012 Q2 | -573.46 Thousand ILS | 0.0% |
| 2012 Q3 | -3.7 Million ILS | -546.69% |
| 2012 Q4 | -2.29 Million ILS | 38.15% |
| 2012 Q1 | -573.46 Thousand ILS | -105.86% |
| 2011 Q1 | 9.78 Million ILS | 0.0% |
| 2011 FY | 39.14 Million ILS | 0.0% |
| 2011 Q2 | 9.78 Million ILS | 0.0% |
| 2011 Q3 | 9.78 Million ILS | 0.0% |
| 2011 Q4 | 9.78 Million ILS | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Avadel Pharmaceuticals plc | 4.21 Million USD | -2141.831% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | -0.351% |
| Biofrontera Inc. | 4.05 Million USD | -2230.819% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 78.284% |
| Journey Medical Corporation | -9.7 Million USD | 1073.715% |
| Dynavax Technologies Corporation | 106.63 Million USD | 11.344% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 84.835% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 22.445% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 78.154% |
| ProPhase Labs, Inc. | 19.23 Million USD | -391.592% |
| Radius Health, Inc. | 359.28 Million USD | 73.687% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | -26.135% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 704.67% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 704.67% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 2038.446% |
| SCYNEXIS, Inc. | -19.35 Million USD | 588.568% |
| Safety Shot Inc | -2.28 Million USD | 4238.462% |
| SIGA Technologies, Inc. | -148.68 Million USD | 163.584% |
| Bright Green Corporation | 1.84 Million USD | -5033.125% |
| Silver Spike Investment Corp. | -32.61 Million USD | 389.89% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 1102.552% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 2063.814% |
| Theratechnologies Inc. | 24.87 Million USD | -280.113% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -88369.853% |
| Talphera, Inc. | -5.72 Million USD | 1752.473% |
| Tilray Brands, Inc. | 158.97 Million USD | 40.534% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 1586.529% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -2470.364% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -47837.974% |
| Procaps Group, S.A. | 242.93 Million USD | 61.085% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 748.765% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 3851.508% |
| Alvotech | 1.06 Billion USD | 91.117% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 1922.935% |
| Alimera Sciences, Inc. | 55.3 Million USD | -70.927% |
| Cosmos Health Inc. | 8.59 Million USD | -1000.462% |
| Phibro Animal Health Corporation | 454.84 Million USD | 79.215% |
| Alpha Teknova, Inc. | 1.97 Million USD | -4689.159% |
| Cronos Group Inc. | -663.32 Million USD | 114.252% |
| Harrow Health, Inc. | 116.41 Million USD | 18.794% |
| OptiNose, Inc. | 58.06 Million USD | -62.814% |
| Rockwell Medical, Inc. | 4.45 Million USD | -2021.589% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 6450.279% |
| Shineco, Inc. | 29.29 Million USD | -222.762% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 381.976% |
| DURECT Corporation | -7.65 Million USD | 1335.145% |
| Incannex Healthcare Limited | -5.48 Million USD | 1823.573% |
| Procaps Group S.A. | 242.93 Million USD | 61.085% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 1968.198% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 172.261% |
| Viatris Inc. | 17.13 Billion USD | 99.448% |
| PetIQ, Inc. | 351.93 Million USD | 73.138% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 46.679% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -529.708% |
| Assertio Holdings, Inc. | -32.52 Million USD | 390.627% |
| Embecta Corp. | 1.31 Billion USD | 92.794% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 3358.327% |
| PainReform Ltd. | -7.95 Million USD | 1289.157% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 1251.011% |
| Alvotech | 1.06 Billion USD | 91.117% |
| Hempacco Co., Inc. | 13.61 Million USD | -594.383% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | -1223.135% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 197.754% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 79.39% |
| Kamada Ltd. | -46.43 Million USD | 303.607% |
| Indivior PLC | -33.95 Million USD | 378.446% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -36180.673% |
| Flora Growth Corp. | -713 Thousand USD | 13359.187% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 1251.011% |
| Evolus, Inc. | 63.7 Million USD | -48.393% |
| HUTCHMED (China) Limited | -197.45 Million USD | 147.878% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 80.268% |
| Akanda Corp. | 3.9 Million USD | -2321.0% |